Nextremity Solutions Gains FDA Clearance for Cannulated Hammertoe System

Nextremity Solutions received FDA 510(k) clearance to market its upcoming DuoHex™ CH System, indicated for small bone reconstruction limited to interphalangeal repair and fusion of the lesser toes.

The DuoHex CH System addresses hammertoe deformity and provides a novel two-piece threaded implant construct designed for optimum bone purchase. The design of the cannulated implants and instruments provide targeting and technique guidance for repeatable outcomes. Implant-to-implant rotational stability is made possible by the implant’s hexagonal locking mechanism.

Ryan Schlotterback, Chief Technology Officer, said, “Nextremity Solutions was founded years ago by surgeons with a passion for the foot and ankle market and with an innovative solution for hammertoe correction. After all this time, it was fun to revisit this common foot procedure and have the engineers go back to the drawing board. The team has done a fantastic job of taking our rich heritage and combining all we’ve learned over the years to commercialize another great solution for hammertoe correction. We’re excited about adding the DuoHex CH System to our rapidly expanding portfolio.”